全文获取类型
收费全文 | 491篇 |
免费 | 20篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 10篇 |
妇产科学 | 11篇 |
基础医学 | 61篇 |
口腔科学 | 5篇 |
临床医学 | 69篇 |
内科学 | 102篇 |
皮肤病学 | 12篇 |
神经病学 | 22篇 |
特种医学 | 7篇 |
外科学 | 77篇 |
综合类 | 33篇 |
预防医学 | 24篇 |
眼科学 | 4篇 |
药学 | 40篇 |
肿瘤学 | 22篇 |
出版年
2013年 | 6篇 |
2012年 | 3篇 |
2010年 | 9篇 |
2009年 | 12篇 |
2007年 | 3篇 |
2004年 | 2篇 |
2003年 | 2篇 |
2001年 | 7篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 7篇 |
1997年 | 16篇 |
1996年 | 18篇 |
1995年 | 7篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 9篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 10篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1972年 | 3篇 |
1969年 | 2篇 |
1967年 | 3篇 |
1965年 | 4篇 |
1963年 | 4篇 |
1959年 | 29篇 |
1958年 | 40篇 |
1957年 | 31篇 |
1956年 | 32篇 |
1955年 | 29篇 |
1954年 | 44篇 |
1949年 | 18篇 |
1948年 | 34篇 |
1947年 | 2篇 |
1946年 | 7篇 |
排序方式: 共有512条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
C. J. McCARTHY R. COLLINS S. BEATTIE H. HAMILTON C. O'MORAIN 《Alimentary pharmacology & therapeutics》1993,7(4):463-466
Omeprazole heals most duodenal ulcers after 4 weeks of treatment but relapse is common. Eradication of Helicobacter pylori is associated with reduced rate of ulcer relapse. This study investigates the effect of omeprazole with antibiotics in H. pylori-associated duodenal ulceration. Forty-three patients with endoscopically proven duodenal ulcer and H. pylori entered this study. Treatment consisted of 20 mg omeprazole daily (four weeks) and seven days (first week) treatment with 400 mg metronidazole t.d.s. and 500 mg tetracycline t.d.s. Four weeks after completing the treatment, 81 % (35143) had a healed duodenal ulcer, and 58% (25/43) had H. pylori eradication. In those who healed, at one year 21 remained H. pylori-negative, 12 had persistent H. pylori infection and 2 had re-infection. The ulcer relapse rate at one year was 26%: of the 9 who relapsed, 6 had persistent infection, 2 were re-infected, and only 1 was H. pylori-negative. This combination therapy of antibiotics with omeprazole successfully eradicates Helicobacter pylori and has a lower ulcer replase than omeprazole alone. 相似文献
8.
Jaclyn YOONG Jo‐An SEAH Katherine HAMILTON Lee Na TEO Geoffrey CHONG 《Asia-Pacific Journal of Clinical Oncology》2012,8(4):325-329
Aims: Benefits to patients from systemic anti‐cancer therapies (SACT) occur at a cost of significant toxicities that can be life threatening. Published data of SACT mortality outside clinical trials is limited with no published Australia data. We aim to establish local outcomes at a regional Victorian oncology center to allow comparison with limited international data. Methods: An audit was undertaken at Ballarat Health Services to analyze all deaths occurring within 30 and 60 days of receiving SACT (cytotoxic chemotherapy and targeted therapy) for epithelial malignancies and hematological malignancies (excluding acute leukemia), over a 12‐month period. Hormonal therapy was excluded. Results: Between 1 January and 31 December 2008, 378 patients received SACT. In total 13 deaths (3.4%) occurred within 30 days following SACT. Three deaths (23%) were definitely treatment‐related – neutropenic sepsis, pneumocystis pneumonia and bowel perforation, respectively. Eight deaths (62%) were definitely unrelated to treatment. Most deaths were due to disease progression (six patients) For two patients (15%), the cause of death was unknown. Most patients were treated with palliative intent. Most patients were receiving first‐line treatment (seven patients, 50%). A further five deaths (1.3%) occurred 31–60 days after SACT, four of which were due to disease progression. Conclusion: Our local outcome data are comparable to limited current international data. This type of audit reviews local outcomes and identifies factors contributing to mortality in order to improve standards of care. We encourage similar audits to establish national benchmarks of 30‐day mortality rate. 相似文献
9.
INGE O. BAAS FRANK M. VAN DEN BERG JAN-WILLEM R. MULDER MARJON J. CLEMENT ROBBERT J. C. SLEBOS STANLEY R. HAMILTON G. JOHAN A. OFFERHAUS 《The Journal of pathology》1996,178(3):264-267
Aberrant crypt foci (ACF) are putative precursor lesions of colon cancer, recently identified on the methylene blue-stained mucosal surface of human colon. No mutations in K- ras or p53 genes were found by non-radioactive single-strand conformation polymorphism analysis in 14 ACF collected from five patients. Using the more sensitive method of allele-specific polymerase chain reaction (PCR) for K- ras , 8 of 14 ACF were found to contain K- ras mutations, suggesting that mutated cells are present in minute clones in ACF. No dysplasia was observed in any of the ACF containing a mutated clone. The presence of K- ras mutations in ACF suggests that these lesions occur at a very early stage in human colorectal carcinogenesis. 相似文献
10.
GARY W. SMALL LON S. SCHNEIDER S. H. HAMILTON ALEXANDER BYSTRITSKY BARNETT S. MEYERS CHARLES B. NEMEROFF FLUOXETINE COLLABORATIVE STUDY GROUP 《International journal of geriatric psychiatry》1996,11(12):1089-1095
We studied differences in outcome and characteristics among 29 clinical sites of a multisite, double-blind antidepressant trial for geriatric depression. Six hundred and seventy-one outpatients aged 60 years or older (mean±SD=67.7±5.7) met DSM-III-R criteria for unipolar major depression, had baseline 17-item Hamilton Depression Rating Scale (HAMD17) scores ≥16 and were randomized to fluoxetine (20 mg daily) or placebo. Effect sizes (ESs, expressed as mean differences between effects divided by the pooled standard deviation of the differences) were calculated for each site using selected outcome measures. ES ranged from 1.84 (favoring fluoxetine) to −0.91 (favoring placebo) for incidence of remitters (endpoint HAMD17 total score of ≤8). A large, positive ES favoring fluoxetine for remission rates (ES≥0.65) was found at only six sites, moderate ES (0.35–0.64) at eight and small ES (0–0.34) at seven; ES favored placebo (<0) at eight of 29 sites. Private clinics showed an overall HAMD17 ES for change scores more than twice that of university sites. These results suggest that individual practitioners may have vastly different clinical experiences in large, multisite trials for geriatric depression. Interrater reliability, subject selection, recruitment, inadequate or fixed dosing, few patients per site, brief study duration, heterogeneity of geriatric depression, financial incentive and characteristics of individual sites may contribute to response variability. 相似文献